

## **A real life experience of IBD patients treated with biologic treatment vs immunomodulators**

Rami George Maalouf, Hani Waked, Charbel Yazbeck, Caline Azzi, Michel Dagher, Souheil Hallit and Yara Assaf  
Holy Spirit University of Kaslik, Lebanon

**T**reatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving approach, with much ongoing studies to determine the outcomes safety and side effects, in comparison to the older immunosuppressive treatment regimens. In this research, a retrospective analysis was conducted on 112 patients with IBD, retrieved from a single center in Lebanon, with the aim of evaluating the outcomes of biologic, immunosuppressive, or combination of both drug classes, over one another, in the treatment of patients with IBD in the real life experience. Patient treated with Azathioprine were 58%, patients receiving Inliximab were 13%, 20% received Adalimumab, and only 8.9% of

### **Notes:**